Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.
Study Type
OBSERVATIONAL
Enrollment
100
Collection of saliva, urine, blood, breath and quality of life questionnaires.
Imperial College Healthcare NHS Trust
London, United Kingdom
RECRUITINGSalivary microbial biomarkers to predict treatment response and long-term prognosis
Changes in the presence and/or abundance of bacteria over a 2 year period, measured primarily within saliva.
Time frame: 48 months
Breath volatile organic compound profile alterations of oesophagogastric cancer pre- and post- treatment
Changes in the VOC profile using gas chromatography mass spectrometry.
Time frame: 48 months
Quality of life measure up to 2 years following cancer surgery using validated questionnaires
Assessment in the longitudinal changes of quality of life measures using validated questionnaires.
Time frame: 48 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.